NEWS

Press Releases AND Media
Press Releases

Aurora Bio, Inc Announces Clinical Data on Lead Program

businesswire.com
Source Author:

December 8, 2019
PDF Version
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free

05:42 PM Eastern Standard Time

Retention of the radiotracer was also observed in the nerves, ligaments, and lungs in patients with Transthyretin amyloidosis (ATTR) and kidney, spleen, adrenal glands and liver in patients with Leukocyte cell-derived chemotaxin 2 amyloidosis (ALECT2). 100% of ATTR patients had cardiac uptake, including 50% of patients with no cardiac symptoms, normal cardiac biomarkers and one patient with a negative pyrophosphate scan (but confirmed via endomyocardial biopsy).

ORLANDO, Fla.--(BUSINESS WIRE)--Aurora Bio, Inc www.Aurorabioinc.com today announced data for the company’s novel PET radiotracer, AUR01, in development for systemic amyloidosis, was presented by Dr. Jonathan Wall, at ASH2019, in Orlando, FL.

Spencer Guthrie, Chief Executive Officer, stated, “We are very excited about the results presented today on 1st 18 patients scanned with the investigational radiotracer, AUR01. We were excited to detect multiple organs in AL, ATTR and ALECT2 patients, and particularly asymptomatic organs. These diseases are truly systemic, yet the ability to determine the extent of organ involvement has been limited by current technologies.

05:42 PM Eastern Standard Time

Retention of the radiotracer was also observed in the nerves, ligaments, and lungs in patients with Transthyretin amyloidosis (ATTR) and kidney, spleen, adrenal glands and liver in patients with Leukocyte cell-derived chemotaxin 2 amyloidosis (ALECT2). 100% of ATTR patients had cardiac uptake, including 50% of patients with no cardiac symptoms, normal cardiac biomarkers and one patient with a negative pyrophosphate scan (but confirmed via endomyocardial biopsy).

ORLANDO, Fla.--(BUSINESS WIRE)--Aurora Bio, Inc www.Aurorabioinc.com today announced data for the company’s novel PET radiotracer, AUR01, in development for systemic amyloidosis, was presented by Dr. Jonathan Wall, at ASH2019, in Orlando, FL.

Spencer Guthrie, Chief Executive Officer, stated, “We are very excited about the results presented today on 1st 18 patients scanned with the investigational radiotracer, AUR01. We were excited to detect multiple organs in AL, ATTR and ALECT2 patients, and particularly asymptomatic organs. These diseases are truly systemic, yet the ability to determine the extent of organ involvement has been limited by current technologies.

<< Back to All News

our apologies

TABLET & MOBILE EXPERIENCES
ARE STILL UNDER CONSTRUCTION

Please view on a desktop or laptop computer.